Tumor‐specific but not nonspecific cell‐free circulating DNA can be used to monitor disease response in lymphoma

Recently, nontumor specific circulating DNA was shown to be elevated in a broad range of lymphomas, implicating a role as a potential biomarker. Epstein‐Barr virus' (EBV) presence within a proportion of lymphomas implies EBV‐DNA has potential as a lymphoma‐specific disease response biomarker. However, application would be restricted to EBV‐associated lymphomas. Neither detailed comparison has been performed of lymphoma‐specific versus nonspecific DNA as disease response biomarkers nor have the kinetics of circulating DNA during treatment been established, and the optimal methodology remains unknown. We prospectively evaluated DNA levels and clinical response of 63 lymphoma patients. DNA was measured in paired serum, plasma, and cell samples at five predetermined time‐points taken prior, during and following treatment. Both cell‐free (c‐f) circulating EBV‐DNA (in EBV‐associated lymphoma) and nonspecific c‐f DNA levels (in all lymphomas) were elevated and discriminatory at presentation compared to healthy controls. Nonspecific c‐f DNA was significantly associated with baseline serum lactate dehydrogenase. Within EBV‐associated lymphomas at presentation, there was a strong correlation between specific and nonspecific circulating c‐f DNA (r = 0.9, P < 0.0001). However, only c‐f EBV‐DNA correlated with clinical/radiological response. In addition, c‐f EBV‐DNA, and not nonspecific c‐f DNA, provided an early marker of relapsed and refractory disease. Serum versus plasma, and single versus multiple‐copy EBV‐gene targets were equivalent. Lymphoma‐specific DNA is a disease response biomarker; however, nonspecific DNA reflected neither lymphoma‐specific DNA nor therapeutic response. Lymphoma disease response can be monitored by blood tests, but new lymphoma‐specific biomarkers need to be identified to broaden applicability. Am. J. Hematol. 2012. © 2011 Wiley Periodicals, Inc.

[1]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[2]  K. Kawa,et al.  Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. , 2011, Blood.

[3]  T. Cenci,et al.  The Viral Load of Epstein–Barr Virus (EBV) DNA in Peripheral Blood Predicts for Biological and Clinical Characteristics in Hodgkin Lymphoma , 2011, Clinical Cancer Research.

[4]  N. Amoedo,et al.  Circulating cell-free and Epstein–Barr virus DNA in pediatric B-non-Hodgkin lymphomas , 2010, Leukemia & lymphoma.

[5]  M. Gandhi,et al.  Can a blood test monitor lymphoma? , 2010, Leukemia & lymphoma.

[6]  M. Sol,et al.  Quantitation of whole blood Epstein‐Barr virus DNA is useful for assessing treatment response in patients with non‐Hodgkin’s lymphoma , 2010, International journal of laboratory hematology.

[7]  P. Schlattmann,et al.  Treatment of PTLD with Rituximab and CHOP Reduces the Risk of Renal Graft Impairment after Reduction of Immunosuppression , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  L. Larocca,et al.  Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Fox,et al.  Interlaboratory Comparison of Epstein‐Barr Virus Viral Load Assays , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  M. Gandhi,et al.  A new prognosticator for post‐transplant lymphoproliferative disorders after renal transplantation , 2008, British journal of haematology.

[11]  K. Olthoff,et al.  EBV PCR in the Diagnosis and Monitoring of Posttransplant Lymphoproliferative Disorder: Results of a Two‐Arm Prospective Trial , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Khanna,et al.  Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. , 2006, Blood.

[14]  P. Marlton,et al.  The Hyper‐CVAD chemotherapy regimen has an adverse long‐term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization , 2006, Hematological oncology.

[15]  B. Dörken,et al.  Epstein–Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course , 2006, Annals of Hematology.

[16]  J. Burrows,et al.  Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma , 2006, Clinical Cancer Research.

[17]  M. Gulley,et al.  Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. , 2004, The Journal of molecular diagnostics : JMD.

[18]  W. Au,et al.  Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. , 2004, Blood.

[19]  Yau-Huei Wei,et al.  Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. , 2004, The New England journal of medicine.

[20]  A. Toubert,et al.  Epstein-barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy , 2004, Transplantation.

[21]  D. Chan,et al.  Increased plasma DNA integrity in cancer patients. , 2003, Cancer research.

[22]  D. Porter,et al.  Use of EBV PCR for the Diagnosis and Monitoring of Post‐Transplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Patients , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[24]  P. Bucsky,et al.  PATIENTS AT RISK FOR DEVELOPMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: PLASMA VERSUS PERIPHERAL BLOOD MONONUCLEAR CELLS AS MATERIAL FOR QUANTIFICATION OF EPSTEIN-BARR VIRAL LOAD BY USING REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION1,2 , 2001, Transplantation.

[25]  C. Boucher,et al.  Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus‐associated lymphoproliferative disease after allogeneic stem cell transplantation , 2001, British journal of haematology.

[26]  Jaap M Middeldorp,et al.  Toward Standardization of Epstein-Barr Virus DNA Load Monitoring: Unfractionated Whole Blood as Preferred Clinical Specimen , 2001, Journal of Clinical Microbiology.

[27]  J. Nicolas,et al.  Quantification of Human Cytomegalovirus DNA by Real-Time PCR , 2001, Journal of Clinical Microbiology.

[28]  M. Caligiuri,et al.  Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. , 2000, Blood.

[29]  S. Proctor,et al.  Detection of Epstein‐Barr virus (EBV) genomes in the serum of patients with EBV‐associated Hodgkin's disease , 1999, International journal of cancer.

[30]  T. Morishima,et al.  Quantitative Analysis of Epstein-Barr Virus Load by Using a Real-Time PCR Assay , 1999, Journal of Clinical Microbiology.

[31]  Valeri Vasioukhin,et al.  Point mutations of the N‐ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia , 1994, British journal of haematology.

[32]  J. S. San Miguel,et al.  Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. , 1993, British Journal of Cancer.

[33]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[34]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[35]  H. Mulcahy,et al.  Detection of Circulating Tumour DNA in the Blood (Plasma/Serum) of Cancer Patients , 2004, Cancer and Metastasis Reviews.

[36]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.